Mitsubishi Tanabe Pharma Corporation



Mitsubishi Tanabe Pharma to acquire NeuroDerm Ltd.

July 24, 2017 Masayuki Mitsuka President and Representative Director

Transaction Overview





Mitsubishi Tanabe Pharma

Company: NeuroDerm Ltd.

Transaction Structure:

Transaction Overview

SPC to merge with NeuroDerm after which NeuroDerm will become the surviving entity

Purchase Price: US\$ 39.00 per share (cash)

Transaction Consideration:

US\$ 1,117 million (fully-diluted basis), All-cash

Transaction Schedule:

NeuroDerm to become a wholly owned subsidiary of MTPC upon merger in October 2017

NeuroDerm Ltd.



Company Overview

Name: NeuroDerm Ltd.

- Established: March 18, 2003
- Headquarter: Rehovot, Israel
- Representative: Oded S. Lieberman (CEO)
- Employees: 77 (March 2017)
- Business Description: A clinical-stage pharmaceutical company developing next-generation treatments for CNS disorders including Parkinson's disease
- ◆No. of ordinary shares: 26.3mm shares (as of July 21, 2017)
- Share price: USD 33.20 (NASDAQ Closing Price as of July 21, 2017)
- Listed Exchange: NASDAQ








Key Strengths of NeuroDerm

Creating ideas and R&D capabilities for next-generation treatments for Parkinson's disease that will make a clinically meaningful difference in patients' lives



New drug with significant clinical advantages for patient QOL improvement

to Challenge Unmet Needs of Parkinson's disease ND0612 ND0701

Innovative Pipeline

capabilities

Accelerated lower risk regulatory pathway and short time to market

Strong IP portfolio backed by R&D













Overview of Parkinson's disease



Stage of Parkinson's disease Unmet medical needs Stabilize levodopa plasma concentration Delay or avoid surgery Mild Moderate Severe Manifest, Complete **Motor complications** arm and leg response to tremors, (Off-period, Dyskinesia) levodopa develops

Standard treatment: oral administration of levodopa and carbidopa

Moderate to Severe Parkinson's disease patients may go through **gastrostomy surgical procedures** depending on severity of symptoms

Pipeline Products





Mitsubishi Tanabe Pharma

NeuroDerm has developed patented liquid formulations that, for the first time, enable 24hour, day and night, continuous subcutaneous administration of levodopa and carbidopa to overcome major deficiencies of current treatments, maintain steady therapeutic levodopa levels and offer patients an improved quality of life

Products	Generic Name	Expected Indication	Stage	Target Launch
ND0612	Levodopa / Carbidopa Continuous SC pump / patch pump	Advanced Parkinson's disease	Р3	FY2019
ND0701	Apomorphine Continuous SC pump	Severe Parkinson's disease	P2	-
ND0801	Nicotine and Opipramol, Transdermal	CNS disease Cognition disorders	Ρ2	-

ND0612 pump





ND0612 patch pump (Device in development)



7


ND0612 Profile

Open Up the **Future**



Mitsubishi Tanabe Pharma

ND0612 stabilizes levodopa plasma concentration and improves motor fluctuations without "paying the penalty " of troublesome dyskinesia




Open Up the **Future**



ND0612 PK Results





Source: Jefferies 2017 Global Healthcare Conference. June 6-9, 2017


ND0612 Efficacy



10



ND0612 improves motor fluctuations without "paying the penalty " of troublesome dyskinesia






ND0612 Development Timelines





Simultaneous NDA and EMA submission in FY2018. Target Launch in FY2019

Target early application in US by PK* study with existing drugs



* PK: Pharmacokinetics

Rationale of the Transaction




Rationale of the Transaction

FY 2016

Open Up the **Future**

Medium-Term Management Plan 16-20 Initiatives Mitsubishi Tanabe Pharma



FY 2020

Rationale of the Transaction

Strategic Rationale of NeuroDerm Acquisition



Contribution to FY2020 ¥80 billion U.S. target sales

- Acquisition of global products U.S., Europe, Japan/Asia
- Develop Designed Pharmaceuticals

Open Up the **Future**

Development of MTPC's U.S. franchise





Leverage Radicava business franchise

	Radicava	NeuroDerm products
Specialty	Neurology ALS* specialists	Neurology PD* specialists
Sales team	About 50 people	About 80 people (add about 30 people)
Treatment	amyotrophic lateral sclerosis (orphan disease)	Parkinson's disease patients with moderate to severe
Drug features	First drug to slow decline of physical function of ALS	First drug therapy to stabilize levodopa plasma concentration(24 hours)
Route of administration	Intravenous injection	Subcutaneous injection
Treatment location	Office, Infusion center, Home	Home
Patient support	Searchlight Support	Provide new support program

*ALS: amyotrophic lateral sclerosis, PD: Parkinson's disease

Post-Acquisition Strategy in the U.S.



Post-Acquisition Strategy in the U.S.

Expansion of U.S. Pipeline


Open Up the **Future**



Mitsubishi Tanabe Pharma

Establishing franchise in specialty area around neurological and autoimmune diseases

Approval Targets




Post-Acquisition Strategy in the U.S.

Sustained Growth of the U.S. Business

Open Up the **Future**



After achieving FY2020 U.S. sales of ¥80.0 billion continue to grow as MTPC's second largest business franchise



Transaction Schedule and Outlook





Transaction Schedule

July 2017	MTPC established a local SPC for acquisition in Israel	
July 24, 2017	Definitive Agreement between NeuroDerm, MTPC and MTPC's SPC	
September 2017 (Plan)	NeuroDerm shareholders' meeting. Approval by NeuroDerm's shareholders	
October 2017 (Plan)	SPC to merge with NeuroDerm after which NeuroDerm will become the surviving entity	
October 2017 (Plan)	NeuroDerm to become a wholly owned subsidiary of MTPC upon merger	


Outlook

MTPC is currently examining the potential impact of the acquisition on MTPC's consolidated business results. Additional guidance will be presented after the acquisition procedures have been completed.





Mitsubishi Tanabe Pharma







Mitsubishi Tanabe Pharma

Open Up the Future

Becoming a company that works with a sense of speed and is the first to deliver differentiated value



Cautionary Statement

The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties.